Long-Term Safety of Ixekizumab Treatment in Patients with Psoriasis, Psoriatic Arthritis, or Axial Spondyloarthritis: a Post Hoc Analysis of Cerebro-Cardiovascular Events
Abstract Introduction Psoriasis (PsO), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA) may confer an increased risk for cardiovascular (CV) disease, including major adverse cerebro-cardiovascular events (MACE), deep vein thrombosis (DVT), and pulmonary embolism (PE). Patients with the...
Saved in:
Main Authors: | Mark Lebwohl, Atul Deodhar, Sergio Schwartzman, Carlo Salvarani, Meghan Feely McDonald, Natalia Bello, Elsie L. Grace, Elsa Inman, Andris Kronbergs, Marcus Ngantcha, Proton Rahman, Kim A. Papp, Joseph F. Merola, Alice B. Gottlieb, Andrew Blauvelt |
---|---|
Format: | Article |
Language: | English |
Published: |
Adis, Springer Healthcare
2025-01-01
|
Series: | Dermatology and Therapy |
Subjects: | |
Online Access: | https://doi.org/10.1007/s13555-024-01323-9 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Pregnancy outcomes in patients with psoriasis, psoriatic arthritis, or axial spondyloarthritis receiving ixekizumab
by: A. Egeberg, et al.
Published: (2022-07-01) -
Cambios Funcionales del Cerebro y Psicología
by: Cristian Prado Matte
Published: (2007-01-01) -
Successful Treatment of Linear Psoriasis With the IL-17a-Antagonist Ixekizumab: A Case Report
by: Christov S, et al.
Published: (2025-01-01) -
Spectrum of spondyloarthritis
by: Himanshu Pathak, et al.
Published: (2020-01-01) -
Clinical Characteristics and Treatment Options of Peripheral Spondyloarthritis
by: ZENG Lulu, et al.
Published: (2024-12-01)